Clinical trials: Breakthrough Pain
Pain, Cancer
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.
- Trial name
- NCT00262678
- Testing
- EN3267
- Where
- United States
- Sponsor
- Kyowa Kirin Co., Ltd.
Pain, Breakthrough Cancer Pain
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
The primary objective of this study is to evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain based on Numeric Rating Scale (NRS).
- Trial name
- ACT11705 (NCT01439919)
- Testing
- SSR411298
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sanofi
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01693328)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Archimedes Development Ltd
Breakthrough Cancer Pain
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
The purpose of this observational study is: To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings…
- Trial name
- OASIS (NCT03895762)
- Testing
- Abstral Oral Disintegrating Tablet (ODT)
- Where
- South Korea
- Volunteers
- 143 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Pain
Conversion From Fast Acting Oral Opioids to Abstral®
The purpose of this study is to evaluate safety and efficacy when using a novel dose conversion strategy to switch from immediate release oral opioids to sublingual (SL) fentanyl (Abstral) for treatment of breakthrough cancer…
- Trial name
- NCT01315886
- Testing
- SL fentanyl
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Orexo AB
Cancers, Pain
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00589823
- Testing
- Fentanyl citrate, Immediate release morphine sulphate
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Archimedes Development Ltd
Cancer, Pain
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
The purpose of this study was to assess the 90-day safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain in subjects on around-the-clock opioids for their persistent cancer pain.
- Trial name
- NCT00538863
- Testing
- Fentanyl sublingual spray
- Where
- 52 sites in United States, Canada and 1 more
- Volunteers
- 319 people
- Sponsor
- INSYS Therapeutics Inc
Pain
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Primary: To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®) (hereafter Actiq) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00496392
- Testing
- Nasal fentanyl
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Nycomed
Pain, Cancer
Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients
To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.
- Trial name
- NCT00492388
- Testing
- PMI-150 (intranasal ketamine)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Hospira, now a wholly owned subsidiary of Pfizer
Pain, Cancer
A Phase III Clinical Study of KW-2246
This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.
- Trial name
- NCT00683995
- Testing
- KW-2246 (fentanyl citrate)
- Where
- 20 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Low Back Pain, Migraine
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
- Conditions
- Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
- Trial name
- NCT00228605
- Testing
- OraVescent Fentanyl
- Where
- 38 sites in United States
- Volunteers
- 500 people
- Sponsor
- Cephalon
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Predictable BTP at Swallowing in in Head/Neck Cancer Patients Undergoing Radiotherapy Already Receiving Opioid Therapy for Background Pain
PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy
The primary objective of the present phase IIIb study is to assess the efficacy of FPNS compared with Physician Choice-Usual Care (PC-UC) in the reduction of swallowing predictable BTP in head and neck cancer patients undergoing…
- Trial name
- PERFECT FAST (NCT01980498)
- Testing
- Fentanyl pectin nasal spray (FPNS), Physician choice-Usual care (PC-UC)
- Where
- 25 sites in Italy
- Sponsor
- L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Chronic Low Back Pain
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Low Back Pain
- Trial name
- NCT00214942
- Testing
- ORAVESCENT Fentanyl Citrate
- Where
- 17 sites in United States
- Sponsor
- Cephalon
Cancer, Pain
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Aim of this non-interventional study is to investigate the tolerability of Effentora® in cancer pain patients with breakthrough pain under real-life conditions in clinical practice.
- Trial name
- ERKENTNIS (NCT01400854)
- Testing
- Effentora®
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Cephalon
Pain
Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain
The purpose of the study is to evaluate the efficacy and safety of OraVescent fentanyl treatment compared to placebo treatment monthly over a 12-week treatment period in alleviating breakthrough pain (BTP) in opioid-tolerant…
- Trial name
- NCT00343733
- Testing
- OraVescent Fentanyl
- Where
- 21 sites in United States
- Volunteers
- 120 people
- Sponsor
- Cephalon